Skip to the page

Data / Form D filings / Dualitas Therapeutics, Inc.

Dualitas Therapeutics, Inc.: Form D filing

Dualitas Therapeutics, Inc., a biotechnology company in South San Francisco, CA, filed a Form D with the SEC in 2025. The latest, on November 18, 2025, reports $32.6 million sold of a $66.6 million offering to 7 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
681 GATEWAY BOULEVARD, SUITE 411, South San Francisco, CA, 94080
Phone
(917) 640-1086
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2023
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2091994

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Nov 18, 2025New notice$66,599,990$32,599,997$33,999,9937Jul 7, 2025sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Thomas HudsonDirector
Forbes HuangExecutive Officer
Alicia LeveyDirector
Michael RossDirector
Greg LazarExecutive Officer
Neil WeirDirector
Mark McDadeDirector
Richard MurrayExecutive Officer, Director
Nikola TrbovicDirector

Other biotechnology companies in California that filed recently

Every Form D from the week of Nov 17, 2025 · All recent filings in California · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Dualitas Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.